리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 390 Pages
라이선스 & 가격 (부가세 별도)
한글목차
정밀 투여 세계 시장은 2030년까지 2억 7,340만 달러에 달할 전망
2024년에 1억 8,810만 달러로 추정되는 정밀 투여 세계 시장은 2024-2030년 분석 기간 동안 CAGR 6.4%로 성장하여 2030년에는 2억 7,340만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 소아 환자는 CAGR 7.9%를 기록하며 분석 기간 종료시에는 1억 1,390만 달러에 달할 것으로 예측됩니다. 노인 환자 부문의 성장률은 분석 기간 동안 CAGR 6.0%로 추정됩니다.
미국 시장은 5,130만 달러로 추정, 중국은 CAGR 10.3%로 성장 예측
미국의 정밀 투여 시장은 2024년에 5,130만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간 2024년부터 2030년까지 CAGR 10.3%로 성장하여 2030년에는 예측 시장 규모 5,700만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.1%와 6.3%로 예측됩니다. 유럽에서는 독일이 CAGR 4.2%로 성장할 것으로 예측됩니다.
세계의 정밀 투여 시장 - 주요 동향과 촉진요인 정리
기술 플랫폼은 어떻게 정밀 투여의 정확성과 효율성을 높이는가?
정밀 투여는 헬스케어, 농업, 산업 분야에서 의약품, 화학제품, 생리활성 화합물의 투여 방법을 변화시키고 있습니다. 이 변화의 중심에는 실시간 데이터 분석, 센서 통합, 자동 제어 시스템을 결합하여 높은 정확도로 개별화된 투약을 실현하는 기술이 있습니다. 약물전달 분야에서는 차세대 주입 펌프, 스마트 주사기, 이식형 전달 장치가 마이크로유체공학, MEMS 액추에이터, AI 기반 알고리즘을 활용하여 환자의 나이, 체중, 대사율, 유전자 프로파일에 따라 약물 투여를 최적화하고 있습니다.
포도당, 호르몬 수치, 혈압 등의 바이오마커를 지속적으로 모니터링하고 실시간으로 용량을 조절하는 폐쇄형 루프 시스템은 맞춤형 의료의 중심이 되고 있습니다. 농업 분야에서는 GPS, LiDAR, 다중 스펙트럼 영상처리 등을 활용하여 비료나 작물보호제를 정확한 양만큼 살포하여 환경 유출과 투입물 낭비를 최소화하는 유량 가변형 어플리케이터, 로봇 살포기 등의 정밀 도포 도구가 활용되고 있습니다. 산업용 애플리케이션의 경우, PLC와 통합된 스마트 토출 밸브 및 정량 디스펜서는 식품, 화학 및 화장품 제조에서 토출 정확도를 향상시키고 일관된 제품 품질과 규정 준수를 보장합니다.
정밀 투여 솔루션의 수요를 가장 많이 견인하는 응용 분야는?
헬스케어 분야에서는 종양학, 당뇨병 관리, 마취학, 중환자 치료에서 정밀 투여가 널리 사용되고 있습니다. 약동학 모델링에 기반한 개별화된 화학요법 프로토콜이 개발되어 효능을 유지하면서 독성을 감소시키고 있습니다. 알고리즘에 기반한 볼러스 조절 기능을 갖춘 인슐린 전달 시스템은 당뇨병 환자가 보다 엄격한 혈당 조절을 유지하도록 돕고 있습니다. 투약 민감도가 중요한 소아 및 노인의료 분야에서는 체표면적(BSA) 및 장기 기능 조절형 투약 플랫폼의 채택도 증가하고 있습니다.
농업 분야에서는 정밀 투여 도구가 고부가가치 작물, 양식업, 온실 재배에 널리 도입되고 있습니다. 실시간 영양분 피드백 루프를 갖춘 시비 시스템은 물 부족 지역의 뿌리 영역 효율을 향상시킵니다. 축산 분야에서는 스마트 사료 투여 시스템이 성장률 최적화, 항생제 오남용 감소, 사료 생산 비율 추적에 도움을 주고 있습니다. 의약품 제조 분야에서는 프리필드 주사기 라인, 무균 충전 시스템, 동결건조 약품의 재구성을 위해 정밀 투여를 채택하여 배치의 일관성과 규제 추적성을 보장합니다.
규제 동향과 소비자 기대는 기술 채택을 어떻게 촉진하고 있는가?
FDA, EMA, CDSCO 등 규제 기관은 개별화된 투약과 결과 기반 투약의 중요성을 강조하며, 의약품 개발자와 의료 서비스 제공자에게 정밀 투여 플랫폼의 채택을 촉구하고 있습니다. 모델 정보 의약품 개발(MIDD) 및 생리적 약동학(PBPK) 모델링에 대한 지침은 제약회사들이 의약품 승인 프로세스에 투여 알고리즘을 통합할 것을 촉구하고 있습니다. 마찬가지로, 농업의 환경 규제는 영양분 유출, 농약의 드리프트, 투입물 과다 살포에 따른 온실 가스 배출을 억제하기 위해 정밀 투여 도구의 사용을 촉진하고 있습니다.
맞춤형 헬스케어, 지속가능한 농업, 클린 라벨 식품 생산에 대한 소비자의 기대는 제품 개발 파이프라인을 재구성하고 있습니다. 환자는 부작용이 적은 안전한 약물을 원하고, 소비자는 잔류물이 없는 과일, 채소, 축산물을 원합니다. 그 결과, 서비스 제공업체, 농업 기술 스타트업, 디지털 헬스 플랫폼이 진단, 투약, 모니터링을 통합하는 생태계를 구축하고 있습니다. 데이터 안전성, 상호운용성, 사용자 친화적인 인터페이스는 기술의 수용과 장기적인 채택에 있어 매우 중요한 요소가 되고 있습니다.
세계 정밀 투여 시장의 성장을 가속화하는 요인은 무엇일까?
세계 정밀 투여 시장의 성장을 견인하는 것은 맞춤형 의료에 대한 수요 증가, 투약 정확도에 대한 규제 의무화, 공급망 디지털화 등입니다. 헬스케어 분야에서는 가치 기반 의료로의 전환이 병원과 보험사에게 투약 오류를 줄이고 개인화된 투약 도구를 통해 치료 결과를 개선하도록 유도하고 있습니다. 임상판단지원시스템(CDSS)은 전자건강기록(EHR)과 통합되어 환자 프로필과 검사 결과에 따라 실시간으로 용량을 조정할 수 있도록 권장하고 있습니다.
농업의 경우, 기후변화와 자원 부족으로 인해 농부들은 센서 기반 및 데이터 기반 투약 플랫폼을 통해 투입물 사용 효율을 극대화해야 할 필요성이 대두되고 있습니다. IoT 지원 살포기, 드론 기반 어플리케이터, 위성 가이드 관개 시스템은 소규모부터 대규모 농장 경영에 이르기까지 정밀 도구에 대한 접근성을 확대하고 있습니다. 정부 보조금과 지속가능성에 연동된 농업 대출은 특히 신흥 경제국에서 이러한 기술을 보다 쉽게 이용할 수 있도록 돕고 있습니다.
식품 가공, 화장품, 화학 등의 산업은 품질 기준을 유지하고, 원자재 낭비를 줄이고, 청정 제조 이니셔티브를 지원하기 위해 정밀 투여를 도입하고 있습니다. B. Braun, Bayer CropScience, Thermo Fisher, Syngenta 등 주요 기업들은 디지털 플랫폼, AI 통합, 클라우드 연결에 투자하여 투여 제품 포트폴리오를 강화하고 있습니다. 바이오센서, 기계학습, 원격 진단의 지속적인 발전으로 정밀 투여 시장은 여러 분야에서 지속적인 성장을 기록할 것으로 예상되며, 효율성, 안전성, 개인화를 대규모로 실현할 것으로 예상됩니다.
부문
환자 유형(소아 환자, 노인 환자, 다약제 복용 환자, 말단 장기 기능 장애 환자, 기타 환자 유형), 소프트웨어(웹 기반 소프트웨어, 데스크톱 기반 소프트웨어), 약물 종류(항생제, 항진균제, 면역억제제, 항경련제, 항종양제, 항우울제, 기타 약물 종류별)
조사 대상 기업 사례
ACG Engineering
AptarGroup, Inc.
Becton, Dickinson and Company
Burkert Fluid Control Systems
DEMA Engineering Company
Dover Corporation(PSG)
Endress+Hauser Group
Grundfos Holding A/S
Hamilton Company
Hunan Sanxin Medtec Co., Ltd.
IDEX Corporation
Iwaki Co., Ltd.
KNF Neuberger GmbH
Lutz-Jesco GmbH
Milton Roy(Ingersoll Rand)
Nordson Corporation
ProMinent GmbH
SEKO S.p.A.
Siemens AG(Process Industries)
Watson-Marlow Fluid Technology Solutions(WMFTS)
AI 통합
Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴로 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSM
영문 목차
영문목차
Global Precision Dosing Market to Reach US$273.4 Million by 2030
The global market for Precision Dosing estimated at US$188.1 Million in the year 2024, is expected to reach US$273.4 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Pediatric Patient, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$113.9 Million by the end of the analysis period. Growth in the Geriatrics Patient segment is estimated at 6.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$51.3 Million While China is Forecast to Grow at 10.3% CAGR
The Precision Dosing market in the U.S. is estimated at US$51.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$57.0 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
Global Precision Dosing Market - Key Trends & Drivers Summarized
How Are Technology Platforms Enhancing Accuracy and Efficiency in Precision Dosing?
Precision dosing is transforming how drugs, chemicals, and bioactive compounds are administered across healthcare, agriculture, and industrial sectors. At the heart of this transformation are technologies that combine real-time data analytics, sensor integration, and automated control systems to deliver highly accurate and individualized dosing. In pharmaceuticals, next-generation infusion pumps, smart syringes, and implantable delivery devices are leveraging microfluidics, MEMS actuators, and AI-based algorithms to optimize drug administration based on a patient’s age, weight, metabolic rate, and genetic profile.
Closed-loop systems, which adjust dosing in real-time based on continuous monitoring of biomarkers such as glucose, hormone levels, or blood pressure, are becoming central to personalized medicine. In agriculture, precision dosing tools-such as variable-rate applicators and robotic sprayers-are using GPS, LiDAR, and multispectral imaging to deliver fertilizers and crop protection agents in exact quantities, minimizing environmental runoff and input wastage. In industrial applications, smart dosing valves and volumetric dispensers integrated with PLCs are improving dosing precision in food, chemical, and cosmetics manufacturing, ensuring consistent product quality and regulatory compliance.
Which Application Areas Are Driving the Most Demand for Precision Dosing Solutions?
In healthcare, precision dosing is gaining widespread use in oncology, diabetes management, anesthesiology, and critical care. Personalized chemotherapy protocols are being developed based on pharmacokinetic modeling, reducing toxicity while maintaining efficacy. Insulin delivery systems with algorithm-based bolus adjustments are helping diabetic patients maintain tighter glycemic control. Pediatric and geriatric care, where dosing sensitivity is crucial, are also witnessing increased adoption of body surface area (BSA) and organ-function-adjusted dosing platforms.
In agriculture, precision dosing tools are being deployed extensively in high-value crops, aquaculture, and greenhouse farming. Fertigation systems with real-time nutrient feedback loops are improving root-zone efficiency in water-scarce regions. In animal husbandry, smart feed dosing systems are helping optimize growth rates, reduce antibiotic misuse, and track feed-to-output ratios. The pharmaceutical manufacturing sector is employing precision dosing in prefilled syringe lines, aseptic filling systems, and lyophilized drug reconstitution, ensuring batch consistency and regulatory traceability.
How Are Regulatory Trends and Consumer Expectations Driving Technology Adoption?
Regulatory agencies such as the FDA, EMA, and CDSCO are emphasizing the importance of individualized dosing and outcome-based medication, prompting drug developers and healthcare providers to adopt precision dosing platforms. Guidance on Model-Informed Drug Development (MIDD) and physiologically based pharmacokinetic (PBPK) modeling is encouraging pharmaceutical companies to build dosing algorithms into drug approval processes. Similarly, environmental regulations in agriculture are promoting the use of precision dosing tools to curb nutrient runoff, pesticide drift, and greenhouse gas emissions from over-application of inputs.
Consumer expectations around personalized healthcare, sustainable farming, and clean-label food production are reshaping product development pipelines. Patients are demanding safer drug regimens with fewer side effects, while consumers want residue-free fruits, vegetables, and animal products. As a result, service providers, agritech startups, and digital health platforms are building ecosystems that combine diagnostics, dosing, and monitoring into unified offerings. Data security, interoperability, and user-friendly interfaces are becoming crucial factors in technology acceptance and long-term adoption.
What Forces Are Accelerating the Growth of the Global Precision Dosing Market?
The growth in the global precision dosing market is driven by rising demand for personalized medicine, regulatory mandates for dosing accuracy, and digitalization of supply chains. In healthcare, the shift toward value-based care is pushing hospitals and insurers to reduce medication errors and improve treatment outcomes through individualized dosing tools. Clinical decision support systems (CDSS) are integrating with electronic health records (EHRs) to recommend dosage adjustments in real-time based on patient profiles and laboratory results.
In agriculture, climate change and resource scarcity are compelling farmers to maximize input use efficiency through sensor-based and data-driven dosing platforms. IoT-enabled sprayers, drone-based applicators, and satellite-guided irrigation systems are expanding access to precision tools across small and large farm operations. Government subsidies and sustainability-linked agri-loans are making these technologies more accessible, particularly in developing economies.
Industries such as food processing, cosmetics, and chemicals are embracing precision dosing to maintain quality standards, reduce raw material wastage, and support clean manufacturing initiatives. Major players including B. Braun, Bayer CropScience, Thermo Fisher, and Syngenta are investing in digital platforms, AI integration, and cloud connectivity to strengthen their dosing product portfolios. With ongoing advances in biosensors, machine learning, and remote diagnostics, the precision dosing market is expected to register sustained growth across multiple sectors, enabling efficiency, safety, and personalization at scale.
SCOPE OF STUDY:
The report analyzes the Precision Dosing market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Patient Type (Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction, Other Patient Types); Software (Web-based Software, Desktop-based Software); Drug Class (Antibiotics, Antimycotics, Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
ACG Engineering
AptarGroup, Inc.
Becton, Dickinson and Company
Burkert Fluid Control Systems
DEMA Engineering Company
Dover Corporation (PSG)
Endress+Hauser Group
Grundfos Holding A/S
Hamilton Company
Hunan Sanxin Medtec Co., Ltd.
IDEX Corporation
Iwaki Co., Ltd.
KNF Neuberger GmbH
Lutz-Jesco GmbH
Milton Roy (Ingersoll Rand)
Nordson Corporation
ProMinent GmbH
SEKO S.p.A.
Siemens AG (Process Industries)
Watson-Marlow Fluid Technology Solutions (WMFTS)
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Precision Dosing - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Emphasis on Personalized Medicine Propels Growth in Precision Dosing Technologies
Rising Demand for Targeted Drug Delivery Expands Addressable Market Across Therapeutic Classes
Technological Advancements in Pharmacokinetic Modeling Strengthen Business Case for Dose Optimization
Growth in Biologics and Narrow Therapeutic Index Drugs Throws the Spotlight on Precision Dosing Requirements
Integration of AI and Machine Learning in Dose Algorithms Enhances Clinical Decision-Making
Regulatory Encouragement for Individualized Therapy Approaches Supports Market Development
Expansion of Companion Diagnostics and Genomic Profiling Drives Demand for Patient-Specific Dosing
Use of Real-Time Monitoring Devices Enables Dynamic and Adaptive Dosing Models
OEM Collaborations With Healthcare Providers and Pharma Companies Promote Ecosystem Integration
Shift Toward Minimally Invasive and Microfluidic Delivery Systems Supports Dosing Precision in Chronic Therapy
Increased Clinical Trial Adoption of Adaptive Dosing Protocols Enhances Study Efficiency and Outcomes
Growth in Digital Health and Wearable Biosensors Supports Continuous Biomarker-Driven Dosing
Adoption in Pediatric and Geriatric Care Segments Strengthens Need for Precision and Safety
Focus on Value-Based Healthcare Models and Outcome-Based Contracts Drives Optimal Dosing Strategies
Patient Adherence and Medication Management Apps Improve Feedback Loops in Personalized Therapy
Public and Private Investment in Dose Personalization Infrastructure Enhances Research and Market Entry
Expansion of Home-Based Therapy and Point-of-Care Treatment Promotes Portable Dosing Solutions
Rise in Interest for Individualized Cancer Therapy Accelerates Use of Pharmacogenomics in Dose Planning
Complexity of Drug Interactions and Polypharmacy in Chronic Diseases Supports Need for Dose Adjustment Tools
Educational Initiatives and Clinical Training on Precision Dosing Enhance Market Readiness and Adoption
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Precision Dosing Market Analysis of Annual Sales in US$ for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Precision Dosing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Precision Dosing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Precision Dosing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Pediatric Patient by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Pediatric Patient by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Pediatric Patient by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Geriatrics Patient by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Geriatrics Patient by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Geriatrics Patient by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Patients on Polypharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Patients on Polypharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Patients on Polypharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Patients with End Organ Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Patients with End Organ Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Patients with End Organ Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Patient Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Patient Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Other Patient Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Immunosuppressives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Immunosuppressives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Immunosuppressives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Antiepileptics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Antitumoral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Antitumoral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Antitumoral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 31: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 34: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 37: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Antimycotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Antimycotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 40: World 16-Year Perspective for Antimycotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Web-based Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 42: World Historic Review for Web-based Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 43: World 16-Year Perspective for Web-based Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Desktop-based Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 45: World Historic Review for Desktop-based Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 46: World 16-Year Perspective for Desktop-based Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 47: USA Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 49: USA 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 52: USA 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 54: USA Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 55: USA 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
CANADA
TABLE 56: Canada Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 58: Canada 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 61: Canada 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 64: Canada 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
JAPAN
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 65: Japan Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 67: Japan 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 70: Japan 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 73: Japan 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
CHINA
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 74: China Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 75: China Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 76: China 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 78: China Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 79: China 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 81: China Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 82: China 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
EUROPE
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 83: Europe Recent Past, Current & Future Analysis for Precision Dosing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Precision Dosing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 85: Europe 16-Year Perspective for Precision Dosing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 88: Europe 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 91: Europe 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 94: Europe 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
FRANCE
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 95: France Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 96: France Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 97: France 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 99: France Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 100: France 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 101: France Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 102: France Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 103: France 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
GERMANY
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 104: Germany Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 106: Germany 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 107: Germany Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 109: Germany 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 110: Germany Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 111: Germany Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 112: Germany 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
ITALY
TABLE 113: Italy Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 115: Italy 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 118: Italy 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 119: Italy Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 120: Italy Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 121: Italy 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
UNITED KINGDOM
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 122: UK Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 123: UK Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 124: UK 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 125: UK Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 126: UK Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 127: UK 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 128: UK Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 129: UK Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 130: UK 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
SPAIN
TABLE 131: Spain Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 132: Spain Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 133: Spain 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 134: Spain Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 135: Spain Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 136: Spain 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 137: Spain Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 138: Spain Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 139: Spain 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
RUSSIA
TABLE 140: Russia Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 141: Russia Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 142: Russia 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 143: Russia Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 144: Russia Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 145: Russia 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 146: Russia Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 147: Russia Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 148: Russia 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 150: Rest of Europe Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 151: Rest of Europe 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 153: Rest of Europe Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 154: Rest of Europe 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 156: Rest of Europe Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 157: Rest of Europe 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Precision Dosing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Precision Dosing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for Precision Dosing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 163: Asia-Pacific 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 165: Asia-Pacific Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 166: Asia-Pacific 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 168: Asia-Pacific Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 169: Asia-Pacific 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
AUSTRALIA
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 170: Australia Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 171: Australia Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 172: Australia 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 173: Australia Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 174: Australia Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 175: Australia 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 176: Australia Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 177: Australia Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 178: Australia 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
INDIA
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 179: India Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 180: India Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 181: India 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 182: India Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 183: India Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 184: India 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 185: India Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 186: India Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 187: India 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 188: South Korea Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 189: South Korea Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 190: South Korea 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 191: South Korea Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 192: South Korea Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 193: South Korea 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 194: South Korea Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 195: South Korea Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 196: South Korea 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 198: Rest of Asia-Pacific Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Asia-Pacific Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Asia-Pacific Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
LATIN AMERICA
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 206: Latin America Recent Past, Current & Future Analysis for Precision Dosing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Precision Dosing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 208: Latin America 16-Year Perspective for Precision Dosing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 209: Latin America Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 210: Latin America Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 211: Latin America 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 212: Latin America Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 213: Latin America Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 214: Latin America 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 215: Latin America Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 216: Latin America Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 217: Latin America 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 218: Argentina Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 219: Argentina Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 220: Argentina 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 221: Argentina Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 222: Argentina Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 223: Argentina 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 224: Argentina Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 225: Argentina Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 226: Argentina 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
BRAZIL
TABLE 227: Brazil Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 228: Brazil Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 229: Brazil 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 230: Brazil Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 231: Brazil Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 232: Brazil 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 233: Brazil Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 234: Brazil Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 235: Brazil 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
MEXICO
TABLE 236: Mexico Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 237: Mexico Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 238: Mexico 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 239: Mexico Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 240: Mexico Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 241: Mexico 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 242: Mexico Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 243: Mexico Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 244: Mexico 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 246: Rest of Latin America Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 247: Rest of Latin America 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 249: Rest of Latin America Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 250: Rest of Latin America 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 252: Rest of Latin America Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 253: Rest of Latin America 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
MIDDLE EAST
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 254: Middle East Recent Past, Current & Future Analysis for Precision Dosing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Precision Dosing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 256: Middle East 16-Year Perspective for Precision Dosing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 257: Middle East Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 258: Middle East Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 259: Middle East 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 260: Middle East Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 261: Middle East Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 262: Middle East 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 263: Middle East Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 264: Middle East Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 265: Middle East 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
IRAN
TABLE 266: Iran Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 267: Iran Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 268: Iran 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 269: Iran Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 270: Iran Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 271: Iran 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 272: Iran Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 273: Iran Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 274: Iran 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
ISRAEL
TABLE 275: Israel Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 276: Israel Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 277: Israel 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 278: Israel Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 279: Israel Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 280: Israel 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 281: Israel Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 282: Israel Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 283: Israel 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 285: Saudi Arabia Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 286: Saudi Arabia 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 288: Saudi Arabia Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 289: Saudi Arabia 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 291: Saudi Arabia Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 292: Saudi Arabia 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 293: UAE Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 294: UAE Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 295: UAE 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 296: UAE Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 297: UAE Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 298: UAE 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 299: UAE Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 300: UAE Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 301: UAE 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 303: Rest of Middle East Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 304: Rest of Middle East 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 306: Rest of Middle East Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 307: Rest of Middle East 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 309: Rest of Middle East Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 310: Rest of Middle East 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030
AFRICA
Precision Dosing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 311: Africa Recent Past, Current & Future Analysis for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 312: Africa Historic Review for Precision Dosing by Patient Type - Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 313: Africa 16-Year Perspective for Precision Dosing by Patient Type - Percentage Breakdown of Value Sales for Pediatric Patient, Geriatrics Patient, Patients on Polypharmacy, Patients with End Organ Dysfunction and Other Patient Types for the Years 2014, 2025 & 2030
TABLE 314: Africa Recent Past, Current & Future Analysis for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 315: Africa Historic Review for Precision Dosing by Drug Class - Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 316: Africa 16-Year Perspective for Precision Dosing by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Other Drug Classes, Antibiotics and Antimycotics for the Years 2014, 2025 & 2030
TABLE 317: Africa Recent Past, Current & Future Analysis for Precision Dosing by Software - Web-based Software and Desktop-based Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 318: Africa Historic Review for Precision Dosing by Software - Web-based Software and Desktop-based Software Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
TABLE 319: Africa 16-Year Perspective for Precision Dosing by Software - Percentage Breakdown of Value Sales for Web-based Software and Desktop-based Software for the Years 2014, 2025 & 2030